Milestone Pharmaceuticals MIST 深 沪
等待开盘 03-26 09:30:00 美东时间
1.25
+0.090
+7.76%
华盛通- 最 高1.26
- 今 开1.175
- 成交量 176.62万股
- 最 低 1.17
- 昨 收 1.16
- 总市值 1.06亿
- 52周最高 3.06
- 市盈率 静 --
- 换手率 2.07%
- 52周最低 0.6254
- 委 比 29.70%
- 总股本 8516.93万
- 历史最高 27.95
- 量 比 0.55
- 振 幅 7.76%
- 历史最低 0.6254
- 每 手 1
- 风险率 0.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Azitra (AMEX:AZTR) stock rose 52.6% to $0.27 during Friday's regular s...
03-21 01:06
Why Milestone Pharma Stock Is Taking A Dive Today
EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.
03-20 23:40
Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last
03-20 19:26
Earnings Scheduled For March 20, 2026
Companies Reporting Before The Bell • BitFuFu (NASDAQ:FUFU) is likely to report...
03-20 19:11
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.
03-20 14:23
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will report 4Q and full-year 2025 results and provide a business update on Friday, March 20, 2026, followed by a conference call and webcast at 8:30am ET. Participants can join via dial-in numbers (1-877-407-0792 for US, 1-201-689-8263 for international) using conference ID 13759195, or via the webcast link. A replay will be available on the company's website. Milestone is a biopharmaceutical company ...
03-12 12:00
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Milestone Pharmaceuticals Inc. has appointed David Sandoval as General Counsel and Chief Compliance Officer ahead of the launch of CARDAMYST™ (etripamil) nasal spray, the first FDA-approved self-administered treatment for PSVT episodes in adults. Sandoval brings over 15 years of experience in legal and compliance roles across the life sciences sector, with a focus on regulatory approval and commercialization. Joseph Oliveto, Milestone’s President...
02-10 13:00
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Inc. granted 419,000 stock options to two new employees under its 2021 Inducement Plan. The options, with a February 2, 2026 grant date and $1.96 exercise price, vest over four years. The award aligns with Nasdaq Listing Rule 5635(c)(4), applicable to non-employee hires. Milestone is a biopharmaceutical company focused on innovative cardiovascular treatments, including CARDAMYST™ for heart condition management.
02-03 13:00
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
An update from Milestone Pharmaceuticals ( ($MIST) ) is now available. On Janua...
01-26 22:51
Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a rapid commercialization
01-26 21:05
